Skip to main content
SpringerLink
Log in

Cytostatic anticancer drug development: preclinical studies and early clinical trials (Frankfurt/Main, November 1989)

  • Meeting Report
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

MTD:

maximum tolerated dose

AUC:

area under curve

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine I, Technische Universität, Ismaninger Street 22, D-8000, Munich 80, Germany

    Wolfgang E. Berdel

  2. Divison of Hematology and Oncology, Department of Internal Medicine, University of Freiburg, Hugstetterstraße 55, D-7800, Freiburg, Germany

    Heinz -H. Fiebig

Authors
  1. Wolfgang E. Berdel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heinz -H. Fiebig
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This meeting was sponsored by the Association of Medical Oncology (AIO) in the German Cancer Society and organized by the phase I/II-Study Group of the AIO

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berdel, W.E., Fiebig, H.H. Cytostatic anticancer drug development: preclinical studies and early clinical trials (Frankfurt/Main, November 1989). J Cancer Res Clin Oncol 116, 224–227 (1990). https://doi.org/10.1007/BF01612682

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01612682

Keywords

Search

Navigation